PersonGen BioTherapeutics (Suzhou) Co., Ltd.: Leukemia trials

The registry lists 14 Leukemia studies with PersonGen BioTherapeutics (Suzhou) Co., Ltd. as lead sponsor. 3 are open to participants now and 0 have results posted.

Early Phase 1 3Phase 1 8Phase 2 5No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT05731219Phase 1
• TAA05 Injection in the Treatment of Adult Patients With FLT3-positive Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT05432401Early Phase 1
• TAA05 Cell Injection in the Treatment of Recurrent / Refractory Acute Myeloid LeukemiaRecruitingNCT05017883Not applicable
• Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid LeukemiaStatus unknownNCT05722171Early Phase 1
• CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute LeukemiaStatus unknownNCT04785833Not applicable
• TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid LeukemiaStatus unknownNCT04692948Not applicable
• CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label StudyStatus unknownNCT04480788Phase 1
• γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue RelapseStatus unknownNCT04439721Early Phase 1
• CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic LeukemiaStatus unknownNCT04004637Phase 1
• CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AMLStatus unknownNCT02944162Phase 1/2
• PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and LymphomaStatus unknownNCT02892695Phase 1/2
• Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and LymphomaStatus unknownNCT02851589Phase 1/2
• CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and LymphomaStatus unknownNCT02819583Phase 1/2
• CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and LymphomaStatus unknownNCT02742727Phase 1/2